These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24550570)

  • 21. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
    Lee N; Wald A
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):651-9. PubMed ID: 21446888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacological and clinical profile of linaclotide (Linzess
    Keto Y; Kosako M
    Nihon Yakurigaku Zasshi; 2019; 153(6):289-298. PubMed ID: 31178535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
    Layer P; Stanghellini V
    Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
    Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.
    Atluri DK; Chandar AK; Bharucha AE; Falck-Ytter Y
    Neurogastroenterol Motil; 2014 Apr; 26(4):499-509. PubMed ID: 24351035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome.
    Sood R; Ford AC
    Ther Adv Chronic Dis; 2013 Nov; 4(6):268-76. PubMed ID: 24179669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
    McCormack PL
    Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
    Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a real‑world setting - results from a German noninterventional study.
    Andresen V; Miehlke S; Beck E; Wiseman G; Layer P
    Z Gastroenterol; 2018 Jul; 56(7):738-744. PubMed ID: 29742779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
    Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Nakagawa A; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13442. PubMed ID: 30084233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.
    Farmer AD; Ruffle JK; Hobson AR
    Neurogastroenterol Motil; 2019 Feb; 31(2):e13492. PubMed ID: 30353623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linaclotide for the treatment of chronic constipation.
    Bassotti G; Usai-Satta P; Bellini M
    Expert Opin Pharmacother; 2018 Aug; 19(11):1261-1266. PubMed ID: 29985664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study.
    Taylor DCA; Abel JL; Doshi JA; Martin C; Goolsby Hunter A; Essoi B; Korrer S; Reasner DS; Carson RT; Chey WD
    J Clin Gastroenterol; 2019; 53(10):737-743. PubMed ID: 31361710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI; Bouras EP
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.
    Lacy BE; Levenick JM; Crowell MD
    Gastroenterol Hepatol (N Y); 2012 Oct; 8(10):653-60. PubMed ID: 24683372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.